These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 7518631)

  • 1. [The role of LH-RH analogue in benign prostatic hyperplasia].
    Ferretti S; Salsi P; Arena F; Peracchia G; Cortellini P
    Acta Biomed Ateneo Parmense; 1993; 64(1-2):23-7. PubMed ID: 7518631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia.
    Peters CA; Walsh PC
    N Engl J Med; 1987 Sep; 317(10):599-604. PubMed ID: 2441256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum free/total prostatic-specific antigen in prostate cancer patients treated with LH-RH agonists.
    Stein A; Barak M; Mecz Y; Rubinov R; Lurie A
    Eur Urol; 1997; 32(1):64-8. PubMed ID: 9266234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of LH-RH analogue in patients with benign prostatic hyperplasia.
    Lukkarinen O
    Urology; 1991 Feb; 37(2):92-4. PubMed ID: 1704161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience.
    Matzkin H; Chen J; Lewysohn O; Braf Z
    J Urol; 1991 Feb; 145(2):309-12. PubMed ID: 1703239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.
    Oesterling JE
    J Androl; 1991; 12(6):381-8. PubMed ID: 1722794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone antagonists.
    Mezo G; Manea M
    Expert Opin Ther Pat; 2009 Dec; 19(12):1771-85. PubMed ID: 19939192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [LH-RH agonists as therapeutic alternative in patients with benign prostatic hyperplasia (BPH) and surgical contraindication. Long term follow up].
    Granados Loarca EA; Chéchile Toniolo G; Villavicencio Mavrich H
    Arch Esp Urol; 1996 Nov; 49(9):923-7. PubMed ID: 9133292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of the quality of life (QOL) of prostatic cancer patients under LH-RH analogue treatment].
    Ueda S; Nishi K; Yoshida M
    Nihon Rinsho; 1998 Aug; 56(8):2119-23. PubMed ID: 9750519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia.
    Debruyne F; Tzvetkov M; Altarac S; Geavlete PA
    Urology; 2010 Oct; 76(4):927-33. PubMed ID: 20932411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
    Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gn-RH analogs and benign prostatic hypertrophy].
    Forti G; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():31-2. PubMed ID: 1706977
    [No Abstract]   [Full Text] [Related]  

  • 16. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparison of the quality of life of prostatic cancer patients under slow releasing LH-RH analogue (TAP-144SR Depot) treatment or synthetic estrogen treatment].
    Oishi K; Arai Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1991 Sep; 37(9):1017-22. PubMed ID: 1785408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist.
    Schlegel PN; Brendler CB
    Urology; 1989 Aug; 34(2):69-72. PubMed ID: 2474882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LH-RH analogues: I. Their impact on reproductive medicine.
    Schally AV
    Gynecol Endocrinol; 1999 Dec; 13(6):401-9. PubMed ID: 10685334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of metastatic MDA-MB-435 human estrogen-independent breast carcinomas with a targeted cytotoxic analogue of luteinizing hormone-releasing hormone AN-207.
    Chatzistamou L; Schally AV; Nagy A; Armatis P; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Oct; 6(10):4158-65. PubMed ID: 11051271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.